
Benjamin P. Blumel
Examiner (ID: 2986, Phone: (571)272-4960 , Office: P/1648 )
| Most Active Art Unit | 1648 |
| Art Unit(s) | 1648, 1671 |
| Total Applications | 1303 |
| Issued Applications | 791 |
| Pending Applications | 143 |
| Abandoned Applications | 404 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18657688
[patent_doc_number] => 20230303633
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => METHODS OF DETECTION AND REMOVAL OF RHABDOVIRUSES FROM CELL LINES
[patent_app_type] => utility
[patent_app_number] => 18/334022
[patent_app_country] => US
[patent_app_date] => 2023-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11067
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18334022
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/334022 | Methods of detection and removal of rhabdoviruses from cell lines | Jun 12, 2023 | Issued |
Array
(
[id] => 18724361
[patent_doc_number] => 20230338503
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => PARENTERAL NOROVIRUS VACCINE FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 18/322679
[patent_app_country] => US
[patent_app_date] => 2023-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17549
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18322679
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/322679 | PARENTERAL NOROVIRUS VACCINE FORMULATIONS | May 23, 2023 | Pending |
Array
(
[id] => 18724361
[patent_doc_number] => 20230338503
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => PARENTERAL NOROVIRUS VACCINE FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 18/322679
[patent_app_country] => US
[patent_app_date] => 2023-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17549
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18322679
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/322679 | PARENTERAL NOROVIRUS VACCINE FORMULATIONS | May 23, 2023 | Pending |
Array
(
[id] => 18724361
[patent_doc_number] => 20230338503
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => PARENTERAL NOROVIRUS VACCINE FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 18/322679
[patent_app_country] => US
[patent_app_date] => 2023-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17549
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18322679
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/322679 | PARENTERAL NOROVIRUS VACCINE FORMULATIONS | May 23, 2023 | Pending |
Array
(
[id] => 18844485
[patent_doc_number] => 20230406889
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-21
[patent_title] => LIVE-ATTENUATED FLAVIVIRUSES WITH HETEROLOGOUS ANTIGENS
[patent_app_type] => utility
[patent_app_number] => 18/312927
[patent_app_country] => US
[patent_app_date] => 2023-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7932
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18312927
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/312927 | LIVE-ATTENUATED FLAVIVIRUSES WITH HETEROLOGOUS ANTIGENS | May 4, 2023 | Pending |
Array
(
[id] => 18626745
[patent_doc_number] => 20230285551
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-14
[patent_title] => LIPIDS AS SYNTHETIC VECTORS TO ENHANCE ANTIGEN PROCESSING AND PRESENTATION EX-VIVO IN DENDRITIC CELL THERAPY
[patent_app_type] => utility
[patent_app_number] => 18/140457
[patent_app_country] => US
[patent_app_date] => 2023-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12971
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18140457
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/140457 | LIPIDS AS SYNTHETIC VECTORS TO ENHANCE ANTIGEN PROCESSING AND PRESENTATION EX-VIVO IN DENDRITIC CELL THERAPY | Apr 26, 2023 | Pending |
Array
(
[id] => 18658061
[patent_doc_number] => 20230304041
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => DUAL PROMOTER-DRIVEN AND DUAL REPORTER-EXPRESSING SARS-COV-2 REPLICONS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/188932
[patent_app_country] => US
[patent_app_date] => 2023-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11906
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18188932
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/188932 | DUAL PROMOTER-DRIVEN AND DUAL REPORTER-EXPRESSING SARS-COV-2 REPLICONS AND METHODS OF USE | Mar 22, 2023 | Pending |
Array
(
[id] => 18531115
[patent_doc_number] => 20230236186
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => LATERAL FLOW ASSAYS FOR NON-DIAGNOSTIC ANALYTES
[patent_app_type] => utility
[patent_app_number] => 18/115253
[patent_app_country] => US
[patent_app_date] => 2023-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8680
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18115253
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/115253 | LATERAL FLOW ASSAYS FOR NON-DIAGNOSTIC ANALYTES | Feb 27, 2023 | Abandoned |
Array
(
[id] => 18692567
[patent_doc_number] => 20230322865
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => Peptides and Combinations of Peptides for Use in Immunotherapy Against an Infection by Sars-COV-2 (COVID-19)
[patent_app_type] => utility
[patent_app_number] => 18/164313
[patent_app_country] => US
[patent_app_date] => 2023-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15866
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18164313
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/164313 | Peptides and Combinations of Peptides for Use in Immunotherapy Against an Infection by Sars-COV-2 (COVID-19) | Feb 2, 2023 | Pending |
Array
(
[id] => 18649429
[patent_doc_number] => 20230295240
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => FcRn-Targeted Mucosal Vaccination Against Influenza Infections
[patent_app_type] => utility
[patent_app_number] => 18/163145
[patent_app_country] => US
[patent_app_date] => 2023-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19340
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18163145
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/163145 | FcRn-targeted mucosal vaccination against influenza infections | Jan 31, 2023 | Issued |
Array
(
[id] => 18752492
[patent_doc_number] => 20230355748
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-09
[patent_title] => DENGUE VACCINE UNIT DOSE AND ADMINISTRATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/149742
[patent_app_country] => US
[patent_app_date] => 2023-01-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 112457
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18149742
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/149742 | DENGUE VACCINE UNIT DOSE AND ADMINISTRATION THEREOF | Jan 3, 2023 | Pending |
Array
(
[id] => 18808977
[patent_doc_number] => 20230383312
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-30
[patent_title] => GENE THERAPY FOR CEROID LIPOFUSCINOSES
[patent_app_type] => utility
[patent_app_number] => 18/148077
[patent_app_country] => US
[patent_app_date] => 2022-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37026
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -41
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18148077
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/148077 | Gene therapy for ceroid lipofuscinoses | Dec 28, 2022 | Issued |
Array
(
[id] => 18467053
[patent_doc_number] => 20230201333
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => EFFICIENT VACCINE
[patent_app_type] => utility
[patent_app_number] => 18/067358
[patent_app_country] => US
[patent_app_date] => 2022-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8043
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18067358
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/067358 | EFFICIENT VACCINE | Dec 15, 2022 | Pending |
Array
(
[id] => 18434441
[patent_doc_number] => 20230181735
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => METHOD OF TREATING INFLUENZA A
[patent_app_type] => utility
[patent_app_number] => 18/063902
[patent_app_country] => US
[patent_app_date] => 2022-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23327
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18063902
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/063902 | Method of treating influenza A | Dec 8, 2022 | Issued |
Array
(
[id] => 18434441
[patent_doc_number] => 20230181735
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => METHOD OF TREATING INFLUENZA A
[patent_app_type] => utility
[patent_app_number] => 18/063902
[patent_app_country] => US
[patent_app_date] => 2022-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23327
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18063902
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/063902 | Method of treating influenza A | Dec 8, 2022 | Issued |
Array
(
[id] => 18467049
[patent_doc_number] => 20230201329
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => INFLUENZA VACCINE
[patent_app_type] => utility
[patent_app_number] => 18/077481
[patent_app_country] => US
[patent_app_date] => 2022-12-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42174
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18077481
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/077481 | INFLUENZA VACCINE | Dec 7, 2022 | Abandoned |
Array
(
[id] => 18657689
[patent_doc_number] => 20230303634
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => OMICRON SARS-COV-2 ASSAY
[patent_app_type] => utility
[patent_app_number] => 18/076315
[patent_app_country] => US
[patent_app_date] => 2022-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11164
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18076315
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/076315 | OMICRON SARS-COV-2 ASSAY | Dec 5, 2022 | Pending |
Array
(
[id] => 18673097
[patent_doc_number] => 20230310571
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => HUMAN METAPNEUMOVIRUS VACCINES
[patent_app_type] => utility
[patent_app_number] => 18/070921
[patent_app_country] => US
[patent_app_date] => 2022-11-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24193
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18070921
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/070921 | HUMAN METAPNEUMOVIRUS VACCINES | Nov 28, 2022 | Pending |
Array
(
[id] => 18709214
[patent_doc_number] => 20230331826
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => AAV-MEDIATED EXPRESSION OF ANTI-INFLUENZA ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/055925
[patent_app_country] => US
[patent_app_date] => 2022-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22822
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18055925
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/055925 | AAV-MEDIATED EXPRESSION OF ANTI-INFLUENZA ANTIBODIES AND METHODS OF USE THEREOF | Nov 15, 2022 | Abandoned |
Array
(
[id] => 19594237
[patent_doc_number] => 12152067
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-26
[patent_title] => Human antibodies to ebola virus glycoprotein
[patent_app_type] => utility
[patent_app_number] => 18/053927
[patent_app_country] => US
[patent_app_date] => 2022-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 28556
[patent_no_of_claims] => 57
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 417
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18053927
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/053927 | Human antibodies to ebola virus glycoprotein | Nov 8, 2022 | Issued |